Ambrx Inks Three-Target Deal With Wyeth To Develop Antibody-Toxin Conjugates
This article was originally published in The Pink Sheet Daily
First license deal for Ambrx's EuCode technology offers potential for "silver bullet" therapeutics that localize pharmacologic activity.
You may also be interested in...
The San Diego biotech has landed another large pharma partner for its antibody-drug conjugation technology as the space continues to attract interest.
Unlike most work in antibody-drug conjugates, however, the collaboration will not focus on oncology but on a broad array of undisclosed targets that may be applicable in a wide variety of indications.
Bristol's second "String of Pearls" transaction in as many days includes a $24 million upfront payment to privately held Ambrx.